GNOM News and Press, Global X Genomics & Biotechnology ETF From 03/16/23

2023-03-16 15:51:00 ET Summary How SVB's collapse is impacting healthcare startups. Pfizer to buy Seagen for $43B. What it means for the sector. Why healthcare startups could face funding challenges. The collapse of Silicon Valley Bank is raising concerns about fun...

2023-03-11 04:42:25 ET Summary Fed's aggressive rate hikes, plus SVB crisis, are a big worry right now. Behind the scenes, a (related) biotech stock crisis is also brewing. Market internals remain weak and demand caution going forward. What do a major U.S. commercial...

2023-03-09 02:50:00 ET Summary Rates of change matter, especially for tech companies, and we would expect investors to react favorably to accelerating growth. In healthcare, we continue to find investment opportunities in a difficult macro environment. If the U.S. enters a tra...

2023-03-09 02:20:00 ET Summary Increasing selling pressure among biotech stocks is a major concern. While the market's intermediate-term path is still up, the short-term outlook is weakening. Beware higher volatility in March as healthcare sector selling pressure persists. ...

Summary We think healthcare companies are quite resilient during periods of inflation because their products are not substitutable and they deliver innovation. Healthcare has lagged behind many other areas in terms of its adoption of technology. We think, regardless of the market en...

Summary We think value stocks can outperform as interest rates head higher. Regions and sectors help us find quality within value and growth at a reasonable price. Stocks slid after the Federal Reserve’s preferred inflation gauge showed persistently high inflation, reinforcing wh...

Summary When I think about the lessons learned from 2022, I think the biggest lesson is valuations matter. I do think this is the most predicted recession that I've ever seen, certainly, in my career. Investors of all stripes, whether you're an asset allocator or a stock picker, I t...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gene editing stocks present themselves as one of the more lucrative investments in the healthcare sector. Gene editing, a revolutionary take on the science of genetic engineering, has the potential to countless lives around t...

Summary Even in its battered condition, the therapeutics sub-sector still accounts for 9.1% of the Russell 2000 Growth index. M&A activity continues to heat up as big players—currently flush with cash—look to drive growth by filling their development pipelines. In ...

Summary Last year’s market volatility was driven primarily by uncertainty over inflation and interest rates. In last year’s downturn, technology stocks were at the epicenter of market volatility. After years of steady gains, investors now acknowledge that technology stocks...